Cargando…
Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations
The development of immune checkpoint inhibitors has revolutionized the landscape of treatment of advanced melanoma in recent years. Based on the efficacy results of the phase III CheckMate 067 trial, nivolumab in combination with ipilimumab is one of the first-line standard options for advanced mela...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315455/ https://www.ncbi.nlm.nih.gov/pubmed/37404764 http://dx.doi.org/10.3389/fonc.2023.1187840 |
_version_ | 1785067507111952384 |
---|---|
author | Vázquez-Montero, Lucía de la Gala, María del Carmen Álamo de la Cruz-Merino, Luis |
author_facet | Vázquez-Montero, Lucía de la Gala, María del Carmen Álamo de la Cruz-Merino, Luis |
author_sort | Vázquez-Montero, Lucía |
collection | PubMed |
description | The development of immune checkpoint inhibitors has revolutionized the landscape of treatment of advanced melanoma in recent years. Based on the efficacy results of the phase III CheckMate 067 trial, nivolumab in combination with ipilimumab is one of the first-line standard options for advanced melanoma along with pembrolizumab, nivolumab, and, recently, nivolumab plus relatlimab. Counterbalancing its efficacy, nivolumab plus ipilimumab is associated with severe immune-related toxicity. This article will review the efficacy and safety of the nivolumab plus ipilimumab combination in advanced melanoma across phase I, II, and III clinical trials that evaluated this approach. We also explore the benefit of the combination schedule across different subgroups of patients and possible predictive biomarkers for efficacy outcomes in order to elucidate which patients could be the best candidates for combination or single-agent therapy. Patients with BRAF-mutant tumours, asymptomatic brain metastases, or PD-L1-negative status appear to reach better survival outcomes with the combination relative to single-agent immunotherapy. |
format | Online Article Text |
id | pubmed-10315455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103154552023-07-04 Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations Vázquez-Montero, Lucía de la Gala, María del Carmen Álamo de la Cruz-Merino, Luis Front Oncol Oncology The development of immune checkpoint inhibitors has revolutionized the landscape of treatment of advanced melanoma in recent years. Based on the efficacy results of the phase III CheckMate 067 trial, nivolumab in combination with ipilimumab is one of the first-line standard options for advanced melanoma along with pembrolizumab, nivolumab, and, recently, nivolumab plus relatlimab. Counterbalancing its efficacy, nivolumab plus ipilimumab is associated with severe immune-related toxicity. This article will review the efficacy and safety of the nivolumab plus ipilimumab combination in advanced melanoma across phase I, II, and III clinical trials that evaluated this approach. We also explore the benefit of the combination schedule across different subgroups of patients and possible predictive biomarkers for efficacy outcomes in order to elucidate which patients could be the best candidates for combination or single-agent therapy. Patients with BRAF-mutant tumours, asymptomatic brain metastases, or PD-L1-negative status appear to reach better survival outcomes with the combination relative to single-agent immunotherapy. Frontiers Media S.A. 2023-06-19 /pmc/articles/PMC10315455/ /pubmed/37404764 http://dx.doi.org/10.3389/fonc.2023.1187840 Text en Copyright © 2023 Vázquez-Montero, de la Gala and de la Cruz-Merino https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Vázquez-Montero, Lucía de la Gala, María del Carmen Álamo de la Cruz-Merino, Luis Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations |
title | Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations |
title_full | Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations |
title_fullStr | Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations |
title_full_unstemmed | Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations |
title_short | Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations |
title_sort | nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315455/ https://www.ncbi.nlm.nih.gov/pubmed/37404764 http://dx.doi.org/10.3389/fonc.2023.1187840 |
work_keys_str_mv | AT vazquezmonterolucia nivolumabplusipilimumabinmetastaticmelanomaacriticalappraisalfocusedonspecificsubpopulations AT delagalamariadelcarmenalamo nivolumabplusipilimumabinmetastaticmelanomaacriticalappraisalfocusedonspecificsubpopulations AT delacruzmerinoluis nivolumabplusipilimumabinmetastaticmelanomaacriticalappraisalfocusedonspecificsubpopulations |